When dosed every 7 or 14 days, IDELVION had a zero median annualized spontaneous and joint bleeding rate.
When dosed at 7 days, IDELVION had an interquartile range, or IQR, of 0 to 0 spontaneous and joint bleeds (IQR at 14 days was 0 to 1 for spontaneous bleeds and 0 to 1.04 for joint bleeds). IQR looks at the middle 50% of people in a clinical study.
“It’s the peace of mind I get having higher factor levels.”
IDELVION is the only FDA-approved Factor IX therapy that lets some people go up to two weeks between doses—while still maintaining high factor levels and prolonged bleed protection. Explore what 14-day* dosing with IDELVION can do.
*Once well controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of ≤40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.
IDELVION delivered high and sustained factor trough levels—20% with prophylactic use at steady state† when dosed every 7 days.
†Steady state is a consistent and uniform amount of factor in the body from continued use.
‡The average dose for people receiving prophylaxis every 7 days was 37 IU/kg and every 14 days was 73 IU/kg.
§The average dose for children receiving prophylaxis every 7 days was 47 IU/kg.
Trough levels are the low point factor levels reach shortly before a new dose. Having high factor levels even at the lowest point between doses means you’re better protected even when you’re most vulnerable.
IDELVION extends half-life using
albumin fusion technology
Real people sharing their
experiences with IDELVION